Company intelligence / Profile preview

Wellstat Group

Gaithersburg, Maryland, United Statesalmacgroup.com ↗

Ownership: Private
Employees: ~11
Development stage: Commercial

Overview

Wellstat Therapeutics has developed and commercialized uridine triacetate for emergency treatment of certain chemotherapy overdoses (Vistogard) and hereditary orotic aciduria (Xuriden). The company also has a pipeline including small molecule therapeutics targeting mitochondrial myopathies, solid tumors, and other indications. Some programs have been discontinued.

Therapeutic areas: OncologyDermatologyRare DiseasesHematology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

uridine triacetate

Commercial

Indications: Hereditary orotic aciduria, 5-fluorouracil toxicity

Beyond the preview

Go deeper on Wellstat Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wellstat Group.

Explore the full profile